Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Endocrine Disruptors in Food, Estrobolome and Breast Cancer

Version 1 : Received: 16 May 2022 / Approved: 17 May 2022 / Online: 17 May 2022 (03:25:56 CEST)
Version 2 : Received: 9 March 2023 / Approved: 10 March 2023 / Online: 10 March 2023 (02:21:55 CET)

A peer-reviewed article of this Preprint also exists.

Filippone, A.; Rossi, C.; Rossi, M.M.; Di Micco, A.; Maggiore, C.; Forcina, L.; Natale, M.; Costantini, L.; Merendino, N.; Di Leone, A.; Franceschini, G.; Masetti, R.; Magno, S. Endocrine Disruptors in Food, Estrobolome and Breast Cancer. J. Clin. Med. 2023, 12, 3158. Filippone, A.; Rossi, C.; Rossi, M.M.; Di Micco, A.; Maggiore, C.; Forcina, L.; Natale, M.; Costantini, L.; Merendino, N.; Di Leone, A.; Franceschini, G.; Masetti, R.; Magno, S. Endocrine Disruptors in Food, Estrobolome and Breast Cancer. J. Clin. Med. 2023, 12, 3158.

Abstract

The microbiota is now recognized as one of the major players in human health and disease, in-cluding cancer. As regards breast cancer (BC), a clear link between microbiota and oncogenesis is still to be confirmed. Yet, part of the bacterial gene mass inside the gut, constituting the so called “estrobolome”, influences the sexual hormonal balance and, since the increased exposure to estrogens is associated with an increased risk, it may impact on the onset, progression, and treatment of hormonal dependent cancers, which account for more than 70% of all BCs. The hormonal dependent BCs are also affected by environmental and dietary endocrine disruptors and phytoestrogens which interact with microbiota in a bidirectional way: on one side disruptors can alter the composition and functions of the estrobolome, on the other the gut microbiota influences the metabolism of endocrine active food components. This review highlights the current evidence about the complex interplay between endocrine disruptors, phytoestrogens, microbiome, and BC, within the frames of a new “oncobiotic” perspective.

Keywords

Microbiome; Endocrine disruptors; Estrobolome; Personalized medicine; Oncobiotic

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.